BioHarvest Sciences Inc. Common Stock
BHST · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.39 | -0.08 | 0.49 | -1.45 |
| FCF Yield | -1.55% | -1.76% | -1.97% | -2.60% |
| EV / EBITDA | -323.07 | -95.16 | -93.03 | -88.05 |
| Quality | ||||
| ROIC | -3.42% | -10.86% | -9.85% | -10.97% |
| Gross Margin | 61.43% | 59.73% | 58.46% | 56.65% |
| Cash Conversion Ratio | 0.84 | 0.37 | 0.61 | 1.00 |
| Growth | ||||
| Revenue 3-Year CAGR | 45.62% | 50.40% | 58.47% | 66.08% |
| Free Cash Flow Growth | -24.10% | 2.98% | 24.12% | -22.50% |
| Safety | ||||
| Net Debt / EBITDA | -16.59 | -12.33 | -11.53 | -8.49 |
| Interest Coverage | -0.60 | -0.82 | -2.96 | -1.34 |
| Efficiency | ||||
| Inventory Turnover | 0.79 | 0.83 | 0.81 | 0.86 |
| Cash Conversion Cycle | 48.63 | 44.66 | 33.30 | 20.24 |